Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.42B P/E - EPS this Y -60.10% Ern Qtrly Grth -
Income -126.09M Forward P/E -8.11 EPS next Y 11.70% 50D Avg Chg -8.00%
Sales 168.34M PEG - EPS past 5Y - 200D Avg Chg -17.00%
Dividend N/A Price/Book 2.08 EPS next 5Y - 52W High Chg -38.00%
Recommedations 1.80 Quick Ratio 7.14 Shares Outstanding 61.65M 52W Low Chg 1.00%
Insider Own 0.94% ROA -9.55% Shares Float 55.28M Beta 0.76
Inst Own 104.40% ROE -18.08% Shares Shorted/Prior 6.22M/5.59M Price 23.52
Gross Margin -50.65% Profit Margin -74.90% Avg. Volume 306,159 Target Price 36.58
Oper. Margin -75.50% Earnings Date May 7 Volume 153,431 Change -2.12%
About Xencor, Inc.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor, Inc. News
05/06/24 Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
05/03/24 Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares
05/02/24 Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
04/09/24 Xencor Appoints Bart Cornelissen as Chief Financial Officer
03/08/24 Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR)
05:00 PM Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)
02/29/24 Xencor Full Year 2023 Earnings: Misses Expectations
02/28/24 Xencor to Present at Upcoming Investor Conferences
02/28/24 Q4 2023 Xencor Inc Earnings Call
02/28/24 Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript
02/27/24 Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
02/27/24 Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023
02/27/24 Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
02/20/24 Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
02/19/24 Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
02/15/24 Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release
01/03/24 Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/03/24 Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?
01/02/24 Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
12/30/23 Insider Sell: Xencor Inc President & CEO Bassil Dahiyat Sells 45,000 Shares
XNCR Chatroom

User Image StockInvest_us Posted - 04/29/24

Signal alert: $XNCR - PivotPoint bottom https://stockinvest.us/l/jsDgTKpSKX

User Image StockInvest_us Posted - 04/18/24

Signal alert: $XNCR - Oversold Trend Short (Undervalued) https://stockinvest.us/l/uOQXEMPAuP

User Image Stocksrunner Posted - 04/16/24

A number of stocks across various sectors - including $CRSR $MRUS $VIPS $XNCR, and $CWH - have recently entered oversold territory based on their RSI readings. Per Warren Buffett's advice, this could signal an opportunity for contrarian investors willing to be "greedy when others are fearful." Time to dig deeper on these potentially undervalued names? 🤔

User Image ViractaTrader77 Posted - 04/14/24

ADC Buying Spree… Sutro Biopharma up next? https://www.labiotech.eu/trends-news/antibody-drug-conjugates-investment-surge/ $STRO $CTMX $BOLT $XNCR

User Image StockInvest_us Posted - 1 month ago

Signal alert: $XNCR - Oversold Trend Short (Undervalued) https://stockinvest.us/l/9Qq0XuTQsa

User Image insiderbuyingselling Posted - 03/12/24

$XNCR new insider selling: 1280 shares. http://insiderbuyingselling.com/?t=XNCR

User Image InsiderPeek Posted - 1 month ago

$XNCR CFO Kuch John J sold 4.5k shares for $104.8k (ownership down 3.54%) insiderpeek.com/company/XNCR

User Image Stock_Titan Posted - 02/28/24

$XNCR Xencor to Present at Upcoming Investor Conferences https://www.stocktitan.net/news/XNCR/xencor-to-present-at-upcoming-investor-irtzx5bxwgu9.html

User Image epsguid Posted - 02/27/24

$XNCR reported a loss of $0.31, consensus was $0.36 via @eWhispers #epsmiss http://eps.sh/d/xncr

User Image Stock_Titan Posted - 02/27/24

$XNCR Xencor Reports Fourth Quarter and Full Year 2023 Financial Results https://www.stocktitan.net/news/XNCR/xencor-reports-fourth-quarter-and-full-year-2023-financial-ooiz699ywnh9.html

User Image TickerDD_com Posted - 02/26/24

From 2/16/2024, looking back across 22 Month-Ends for XNCR, Percentage Change of Average Monthly Price had More Negatives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $XNCR #XNCR #XNCRStock #TickerDD #XNCRPrice https://www.youtube.com/watch?v=qLKbTwkfiJ0

User Image ScoobieDoo Posted - 02/26/24

$XNCR is the Vudalimab update expected to be preliminary results?

User Image Stock_Titan Posted - 02/20/24

$XNCR Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update https://www.stocktitan.net/news/XNCR/xencor-to-host-webcast-to-review-fourth-quarter-and-full-year-2023-cccgbczm0nxp.html

User Image insiderbuyingselling Posted - 02/14/24

$XNCR new insider selling: 54108 shares. http://insiderbuyingselling.com/?t=XNCR

User Image StockInvest_us Posted - 02/09/24

Signal alert: $XNCR - PivotPoint bottom https://stockinvest.us/l/atSWlDydbW

User Image tickeron Posted - 01/24/24

How does this make you feel? $XNCR price exceeded its 50-day Moving Average. View odds of downtrend. https://srnk.us/go/4977429

User Image AnaChart Posted - 01/22/24

$XNCR https://anachart.com/wp-content/uploads/ana_temp/1705935702_soc-img.jpg

User Image Thestocktraderhubzee Posted - 01/22/24

$XNCR Mizuho Maintains Buy on Xencor, Lowers Price Target to $50

User Image cctranscripts Posted - 01/19/24

BlackRock, Inc. just provided an update on share ownership of Xencor Inc https://www.conferencecalltranscripts.org/summary/?id=12879958 $XNCR

User Image UltraAlgo Posted - 01/08/24

$XNCR Sell Rating based off 6 signals, 15-min chart. 💸 Algo Trading at UltraAlgo https://i.redd.it/s8tq1yng8bac1.png

User Image tickeron Posted - 4 months ago

How does this affect your portfolio? $XNCR MACD Histogram turned negative on January 5, 2024. View odds of downtrend. https://srnk.us/go/4961820

User Image StockInvest_us Posted - 4 months ago

Signal alert: $XNCR - Overvalued https://stockinvest.us/l/AypzrOPRdx

User Image Stock_Titan Posted - 4 months ago

$XNCR Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference https://www.stocktitan.net/news/XNCR/xencor-to-present-at-the-42nd-annual-j-p-morgan-healthcare-ruri576k6mxz.html

User Image UltraAlgo Posted - 4 months ago

$XNCR Sell Rating based off 6 signals on the 15-min chart. #XNCR 🚀 Chart by UltraAlgo.com https://i.redd.it/7lretcz0i4ac1.png

User Image StockAutomatePro Posted - 4 months ago

$XNCR Chart analysis suggests a bullish outlook for the stock. We alerted the BUY signal at $21.2 and we were able to close this one with profit at $22.51 🎲

User Image StockInvest_us Posted - 4 months ago

Signal alert: $XNCR - Overvalued https://stockinvest.us/l/8hsDqfgTLM

User Image Stock_Titan Posted - 4 months ago

$XNCR Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy https://www.stocktitan.net/news/XNCR/dane-leone-joins-xencor-as-senior-vice-president-corporate-2zyc428ybal9.html

User Image cctranscripts Posted - 12/29/23

Xencor Inc's PRESIDENT & CEO just picked up 20,001 shares https://www.conferencecalltranscripts.org/summary/?id=12831086 $XNCR

User Image risenhoover Posted - 12/29/23

Insider Bassil I Dahiyat reports selling 45,000 shares of $XNCR for a total cost of $941,670.00 https://fintel.io/n/us/xncr/dahiyat-bassil-i?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=insider

User Image cctranscripts Posted - 12/29/23

Report of proposed sale of securities https://www.conferencecalltranscripts.org/summary/?id=12830695 $XNCR

Analyst Ratings
BTIG Buy Apr 16, 24
Piper Sandler Neutral Feb 28, 24
RBC Capital Outperform Feb 28, 24
BMO Capital Outperform Feb 28, 24
Wedbush Outperform Feb 28, 24
Mizuho Buy Jan 22, 24
Guggenheim Buy Nov 8, 23
RBC Capital Outperform Nov 8, 23
Wedbush Outperform Nov 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Dec 29 Sell 20.93 45,000 941,850 312,929 12/29/23
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Dec 29 Option 11.05 65,001 718,261 357,929 12/29/23
Yang Allen SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CMO Mar 09 Sell 29.8793 1,094 32,688 73,364 03/13/23
Eckert Celia VP, GENERAL COUNSEL VP, GENERAL COUNSEL Mar 09 Sell 29.8793 711 21,244 36,976 03/13/23
Kuch John J SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CFO Mar 09 Sell 29.8793 711 21,244 126,230 03/13/23
Desjarlais John R SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CSO Mar 09 Sell 29.8793 1,230 36,752 147,726 03/13/23
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Mar 09 Sell 29.8793 2,602 77,746 249,701 03/13/23
Yang Allen SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CMO Mar 06 Sell 31.4159 4,069 127,831 74,458 03/08/23
Kuch John J SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CFO Mar 06 Sell 31.4159 2,774 87,148 126,941 03/08/23
Eckert Celia VP, GENERAL COUNSEL VP, GENERAL COUNSEL Mar 06 Sell 31.4159 2,462 77,346 37,687 03/08/23
Desjarlais John R SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CSO Mar 06 Sell 31.4159 4,195 131,790 148,956 03/08/23
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Mar 06 Sell 31.4159 5,831 183,186 252,303 03/08/23
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Mar 02 Sell 31.54 2,851 89,921 258,134 03/06/23
Kuch John J SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CFO Mar 02 Sell 31.54 919 28,985 129,715 03/06/23
Eckert Celia VP, GENERAL COUNSEL VP, GENERAL COUNSEL Mar 02 Sell 31.54 427 13,468 40,149 03/06/23
Desjarlais John R SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CSO Mar 02 Sell 31.54 1,232 38,857 153,151 03/06/23
Yang Allen SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CMO Dec 19 Sell 27.003 3,737 100,910 63,521 12/21/22
Yang Allen SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CMO Mar 09 Sell 28.9362 1,200 34,723 66,529 03/10/22
Kuch John J SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CFO Mar 09 Sell 28.9345 690 19,965 124,591 03/10/22
Eckert Celia VP, GENERAL COUNSEL VP, GENERAL COUNSEL Mar 09 Sell 28.9101 789 22,810 28,976 03/10/22
Desjarlais John R SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CSO Mar 09 Sell 29.1301 1,172 34,140 135,625 03/10/22
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Mar 09 Sell 29.0002 2,494 72,326 207,815 03/10/22
Kuch John J SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CFO Mar 03 Sell 29.86 971 28,994 102,059 03/07/22
Eckert Celia VP, GENERAL COUNSEL VP, GENERAL COUNSEL Mar 03 Sell 29.91 451 13,489 9,861 03/07/22
Desjarlais John R SR. VICE PRESIDENT &.. SR. VICE PRESIDENT & CSO Mar 03 Sell 29.86 1,240 37,026 100,969 03/07/22
Dahiyat Bassil I PRESIDENT & CEO PRESIDENT & CEO Mar 03 Sell 29.9 2,929 87,577 160,548 03/07/22